Dihydrotanshinone I inhibits gallbladder cancer growth by targeting the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation
- PMID: 38677269
- DOI: 10.1016/j.phymed.2024.155661
Dihydrotanshinone I inhibits gallbladder cancer growth by targeting the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation
Abstract
Background: Gallbladder cancer (GBC) poses a significant risk to human health. Its development is influenced by numerous factors, particularly the homeostasis of reactive oxygen species (ROS) within cells. This homeostasis is crucial for tumor cell survival, and abnormal regulation of ROS is associated with the occurrence and progression of many cancers. Dihydrotanshinone I (DHT I), a biologically effective ingredient isolated from Salvia miltiorrhiza, has exhibited cytotoxic properties against various tumor cells by inducing apoptosis. However, the precise molecular mechanisms by which dht I exerts its cytotoxic effects remain unclear.
Purpose: To explore the anti-tumor impact of dht I on GBC and elucidate the potential molecular mechanisms.
Methods: The proliferation of GBC cells, NOZ and SGC-996, was assessed using various assays, including CCK-8 assay, colony formation assay and EdU staining. We also examined cell apoptosis, cell cycle progression, ROS levels, and alterations in mitochondrial membrane potential to delve into the intricate molecular mechanism. Quantitative PCR (qPCR), immunofluorescence staining, and Western blotting were performed to evaluate target gene expression at both the mRNA and protein levels. The correlation between nuclear factor erythroid 2-related factor 2 (Nrf2) and kelch-like ECH-associated protein 1 (Keap1) were examined using co-immunoprecipitation. Finally, the in vivo effect of dht I was investigated using a xenograft model of gallbladder cancer in mice.
Results: Our research findings indicated that dht I exerted cytotoxic effects on GBC cells, including inhibiting proliferation, disrupting mitochondrial membrane potential, inducing oxidative stress and apoptosis. Our in vivo studies substantiated the inhibition of dht I on tumor growth in xenograft nude mice. Mechanistically, dht I primarily targeted Nrf2 by promoting Keap1 mediated Nrf2 degradation and inhibiting protein kinase C (PKC) induced Nrf2 phosphorylation. This leads to the suppression of Nrf2 nuclear translocation and reduction of its target gene expression. Moreover, Nrf2 overexpression effectively counteracted the anti-tumor effects of dht I, while Nrf2 knockdown significantly enhanced the inhibitory effect of dht I on GBC. Meanwhile, PKC inhibitors and nuclear import inhibitors increased the sensitivity of GBC cells to dht I treatment. Conversely, Nrf2 activators, proteasome inhibitors, antioxidants and PKC activators all antagonized dht I induced apoptosis and ROS generation in NOZ and SGC-996 cells.
Conclusion: Our findings indicated that dht I inhibited the growth of GBC cells by regulating the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation. These insights provide a strong rationale for further investigation of dht I as a potential therapeutic agent for GBC treatment.
Keywords: Apoptosis; Dihydrotanshinone I; Gallbladder carcinoma; Keap1-Nrf2 signaling pathway; Oxidative stress.
Copyright © 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation.Free Radic Biol Med. 2022 Feb 20;180:220-235. doi: 10.1016/j.freeradbiomed.2022.01.015. Epub 2022 Jan 21. Free Radic Biol Med. 2022. PMID: 35074488
-
Dihydrotanshinone I inhibits ovarian tumor growth by suppressing ITGB1/FAK-mediated extracellular matrix signaling.Phytomedicine. 2025 Sep;145:157023. doi: 10.1016/j.phymed.2025.157023. Epub 2025 Jun 26. Phytomedicine. 2025. PMID: 40609387
-
aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.Redox Biol. 2019 Apr;22:101149. doi: 10.1016/j.redox.2019.101149. Epub 2019 Feb 21. Redox Biol. 2019. PMID: 30822690 Free PMC article.
-
Panaxatriol saponin ameliorates myocardial infarction-induced cardiac fibrosis by targeting Keap1/Nrf2 to regulate oxidative stress and inhibit cardiac-fibroblast activation and proliferation.Free Radic Biol Med. 2022 Sep;190:264-275. doi: 10.1016/j.freeradbiomed.2022.08.016. Epub 2022 Aug 14. Free Radic Biol Med. 2022. PMID: 35977659 Review.
-
The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism.Int J Mol Sci. 2021 Apr 22;22(9):4376. doi: 10.3390/ijms22094376. Int J Mol Sci. 2021. PMID: 33922165 Free PMC article. Review.
Cited by
-
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease.MedComm (2020). 2025 Jul 1;6(7):e70268. doi: 10.1002/mco2.70268. eCollection 2025 Jul. MedComm (2020). 2025. PMID: 40599237 Free PMC article. Review.
-
Effect of Agkistrodon acutus venom (AAVC-I) on apoptosis through modulation of the Keap1/Nrf2 pathway in HSC-3 oral squamous cell carcinoma cells.Transl Cancer Res. 2024 Aug 31;13(8):4341-4353. doi: 10.21037/tcr-24-182. Epub 2024 Aug 17. Transl Cancer Res. 2024. PMID: 39262468 Free PMC article.
-
Dual role of Nrf2 signaling in hepatocellular carcinoma: promoting development, immune evasion, and therapeutic challenges.Front Immunol. 2024 Sep 2;15:1429836. doi: 10.3389/fimmu.2024.1429836. eCollection 2024. Front Immunol. 2024. PMID: 39286246 Free PMC article. Review.
-
The Central Role of NRF2 in Cancer Metabolism and Redox Signaling: Novel Insights into Crosstalk with ER Stress and Therapeutic Modulation.Cell Biochem Biophys. 2025 Jul 15. doi: 10.1007/s12013-025-01821-3. Online ahead of print. Cell Biochem Biophys. 2025. PMID: 40665070 Review.
-
Matrine inhibits invasion and migration of gallbladder cancer via regulating the PI3K/AKT signaling pathway.Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):8129-8143. doi: 10.1007/s00210-024-03162-z. Epub 2024 May 25. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38789637
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials